|
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Flash Point: | 32.00 °F. TCC ( 0.00 °C. ) (est)
|
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-dog LD50 > 5000 mg/kg
GASTROINTESTINAL: NAUSEA OR VOMITING
BEHAVIORAL: ATAXIA
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1551, 1990.
intravenous-mouse LD50 > 140 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
oral-mouse LD50 > 5000 mg/kg
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1539, 1990.
intravenous-rat LD50 > 100 mg/kg
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1539, 1990.
oral-rat LD50 > 4000 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
intraperitoneal-rat LDLo 1000 mg/kg
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 2589, 1990.
|
| Dermal Toxicity: |
skin-dog LD50 > 100 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
skin-mouse LD50 > 800 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
subcutaneous-mouse LD50 > 200 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
skin-rat LD50 > 1000 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
subcutaneous-rat LD50 > 150 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for butenafine hydrochloride usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for butenafine hydrochloride flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| ClinicalTrials.gov:search |
| Daily Med:search |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :443867 |
| National Institute of Allergy and Infectious Diseases:Data |
| WGK Germany:nwg |
| 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine;hydrochloride |
| Chemidplus:0101827467 |
| RTECS:QJ8585000 for cas# 101827-46-7 |
References:
| | 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine;hydrochloride |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 443867 |
| Pubchem (sid): | 135041927 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | butenafine HCl | | N-4-tert- | butylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride | | N-(p-tert- | butylbenzyl)-N-methyl-1-naphthalenemethylamine hydrochloride | | 1-(4-tert- | butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine;hydrochloride | | N-((4-(1,1- | dimethylethyl)phenyl)methyl)-N-methyl-1-naphthalenemethanamine hydrochloride | | | KP-363 | | | mentax | | | mentax-TC | | 1- | naphthalenemethanamine, N-((4-(1,1-dimethylethyl)phenyl)methyl)-N-methyl-, hydrochloride |
Articles:
| PubMed:Tinea nigra presenting speckled or "salt and pepper" pattern. |
| PubMed:Influence of penetration enhancers and molecular weight in antifungals permeation through bovine hoof membranes and prediction of efficacy in human nails. |
| PubMed:Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. |
| PubMed:Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects. |
| PubMed:Stability-indicating LC assay for butenafine hydrochloride in creams using an experimental design for robustness evaluation and photodegradation kinetics study. |
| PubMed:RP-HPLC method for simultaneous determination of butenafine hydrochloride and betamethasone dipropionate in a cream formulation. |
| PubMed:A simple and rapid method to assess butenafine hydrochloride in skin samples and a comparative cutaneous retention study of two marketed formulations. |
| PubMed:Simultaneous HPLC determination of butenafine hydrochloride and betamethasone in a cream formulation. |
| PubMed:Butenafine and superficial mycoses: current status. |
| PubMed:A Japanese case of tinea corporis caused by Arthroderma benhamiae. |
| PubMed:Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin). |
| PubMed:Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. |
| PubMed:Butenafine hydrochloride: for the treatment of interdigital tinea pedis. |
| PubMed:Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. |
| PubMed:Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. |
| PubMed:A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. |
| PubMed:Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. |
| PubMed:One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. |
| PubMed:Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. |
| PubMed:Two mechanisms of butenafine action in Candida albicans. |
| PubMed:[Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent]. |
| PubMed:Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs. |
| PubMed:Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs. |
|
3D/inchi